This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Cisapride

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Cisapride is a prokinetic drug that previously was licensed for gastro-oesophageal reflux, reduced gastric motility associated with a range of conditions, and non-ulcer dyspepsia.

This drug was withdrawn from marketing in the UK from 28th July 2000 until further notice . This is because cisapride can prolong the QT interval, which may lead to rare but life-threatening ventricular arrythmias. The committee on Safety of Medicines has advised that all treatment with cisapride should be stopped and patients should be changed to an alternative treatment as necessary.

Reference:

  • 1) Committee on Safety of Medicines (July 2000).Suspension of cisapride (Prepulsid): Product withdrawal.

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.